P-GP170、LRP与Ki-67在甲状腺乳头状癌中的表达及临床意义
Expression and Clinical Significance of P-GP170, LRP and Ki-67 in Thyroid Carcinoma
-
摘要: 目的 检测多药耐药基因蛋白P 糖蛋白 (P GP170 )和肺耐药蛋白 (LRP)与抗核抗体Ki 6 7在甲状腺乳头状癌中的表达及临床意义。方法 采用免疫组化SP法检测P GP170、LRP、Ki 6 7在 6 4例甲状腺乳头状癌和 2 0例甲状腺腺瘤中的表达。结果 3种抗体在甲状腺乳头状癌中均呈高表达, 在甲状腺腺瘤中呈低表达。与甲状腺腺瘤相比有显著性差异 (P <0 .0 1)。P GP170、LRP、Ki 6 7三者呈显著相关性 (LRP与Ki 6 7r =0 .4 2, LRP与P GP170r =0 .4 2, Ki 6 7与P GP170r =0 .6 5, P <0 .0 1)。结论甲状腺乳头状癌标记指数高、耐药性强、化疗敏感性低。在化疗中同时给予耐药抑制剂, 可以提高化疗敏感性和化疗效果。Abstract: Objective To investigate expression and clinical significance of P-GP170 (P-glyco-protein, P-GP170),LRP(Lung-Resistance-Protein, LRP) and anti-nuclear antigen Ki-67 in papillary thyroid tumors. Methods SP immunohistochemical technique was used to detect expression of P-GP170, LRP and Ki-67 in 64 cases of papillary thyroid carcinoma and 20 cases of thyroid adenoma. Results P-GP170, LRP and Ki-67 all have high level expression in papillary thyroid carcinoma but low level expression in thyroid adenoma. The di...
下载:
